ATW Tech Provides Additional Information Regarding Signature of a Letter of Intent for Major Acquisition of Greywolf Entertainment Group
Momentum Public Relations
Press Release: November 16, 2018
ATW Tech Inc. (“ATW Tech”) (TSX-V: ATW) has, as previously announced on November 6, 2018, signed a letter of intent for the acquisition from Fastrack Trust (the “Trust”) of all of the outstanding shares of 6855318 Canada Ltd. and 6890202 Canada Ltd. (“Greywolf Entertainment Group” or “Greywolf”). For the unaudited financial year ended December 31, 2017, Greywolf’s revenues were $10.0 million ($11.8 million in 2016) for a net income of $196k ($350k in 2016), with total assets of $2.5 million ($2.4 million) and negative shareholder’ equity of $914k ($759k).
Greywolf Entertainment Group, based in Calgary, provides turnkey full commercial production for interactive TV and/or voting networks required for such shows for landline and mobile consumers. Greywolf’s subsidiaries include Triton Global Business Services Inc. (“Triton”) and Fastrack Global Billing Networks Inc. (“Fastrack”). Triton is a North American clearinghouse that provide billing and networks for phone bills in North America and over 40 other countries. Triton has been listed in the top 300 technology companies from Canada several times. Fastrack is a North American inter-exchange carrier providing networks to its switch centers that intelligently routes consumer traffic to optimized billing or response solutions. Its network is designed to handle mass calling for both short and long periods of time, using its own robust backbone Standard Internet Protocol (SIP) networks to transport traffic anywhere in the world.
The letter of intent contemplates a purchase price of $2.95 million, which is subject to certain adjustments and payable through a cash payment of $2.0 million at closing, a vendor take-back note of $0.3 million payable in 30 equal monthly installments and $0.65 million worth of common shares of ATW Tech. No commission is payable and no change of control will result.
“We are proud to come to an agreement on this strategic acquisition of Greywolf that will help us consolidate our position in the Canadian carrier billing market, accelerate our growth, while almost doubling our revenues, and benefiting from significant cost synergies. Along with the divestiture of the Atman division completed on October 31, 2018, which represented 9.5% of ATW Tech’s revenues in 2017, this contemplated acquisition reflects our will and strategy to concentrate our activities in the financial technologies (“fintech”), particularly on our core integrated payment, interactive communication and voting platforms. This acquisition shall be the first step of our acquisition growth plan with an international reach expected for 2019” said Michel Guay, President and CEO of ATW Tech.
The closing of this transaction between ATW Tech and Greywolf, which are dealing at arm’s length, is conditional among other things on ATW Tech carrying out a satisfactory due diligence on Greywolf, obtaining satisfactory financing and all necessary regulatory approvals (including that of the TSX Venture Exchange). Closing of this transaction is expected before the end of 2018.
The Company also announces that a total of 900 000 share purchase options have been granted to a consultant of the Company at a strike price of $0.10 pursuant to the terms of its share option plan (the “Plan”) and expiring on November 15, 2023.
- Published in Atmanco, ATWTECH, Business, Financial Technology, News Home, Technology
Canadian and US Cannabis Edibles and Consumer Products Market Set to Explode to US$ 4.1 Billion by 2022
Canopy Growth CEO Bruce Linton: “…related cannabis products have the potential to disrupt as much as $500 billion annually in non-smokable areas and industries: alcohol, sleep aids, appetite aids, sports drinks, medicines and pet care.”
If you can read them, the signs are there.
The marijuana edibles industry, that part of the recreational marijuana that be ingested as a candy, a chocolate, a candy bar or in a mixed drink or a beer is going to be huge and may very well eclipse that old standby the smokeable flower or bud.
During the summer ResearchAndMarkets predicted that the global cannabis infused edible products market would grow at an expected CAGR of 25.01% from 2018 to 2022. The infused beverage market would include CBD based
recovery drinks and tonics as well as potent THC infused beers.
An October 11, press release announcing a new report, “The Tasty Future of Cannabis Edibles,” by BDS Analytics and Arcview Research predicted that by 2022 the edibles market would exceed US$4.1 billion, up from US$1.5 billion, for the Canadian and US market in 2018.
A June article in Forbes ran the headline “New Data Shows that Smoking Marijuana is a Dying Trend.” The data it references is the 2018 Deloitte report on the emerging Canadian marijuana market and the Forbes story says, A recent analysis from Deloitte shows that “smokable marijuana” in the northern nation will generate in upwards of $5 billion in 2019. But the edibles sector is predicted to hit somewhere between $12 and $22 billion by the time the market is in full swing.”
According to the BDS and Arcview report the THC infused candy and chocolate market segment took the lion’s share of the US market at 60%. The press release quotes Troy Dayton the CEO of ArcView Market Research: “Established big brand food and beverage companies are beginning to take notice of the cannabis edibles market and this is likely just the tip of the iceberg.”
If anyone doubts that edibles and beverages are the next big thing they should remember Constellation Brands $4 billion investment in Canopy Growth. Of course if that doesn’t convince you then there is also the partnering dance between Coca-Cola and Aurora that somehow didn’t get off the ground. Just how big the market is going to be is still up for grabs.
In a video on TheStreet.com, Canopy Growth CEO Bruce Linton claimed that related cannabis products have the potential to disrupt as much as $500 billion annually in non-smokable areas and industries: alcohol sleep aids appetite aids sports drinks and medicines and pet care.
If you think the $500 billion figure was a bit too high Constellation Brands COO Bill Newlands predicted that the legal cannabis product market would hit $200 billion plus. “Our View is that in the next ten plus years, this is going to be a $200 billion business worldwide. And some would argue that’s understating the case.”
It’s not difficult to see why the edibles market segment is going to take off.
Smoking is, after all, bad for you. The more difficult question to answer maybe how to profit from what will be a long term market build out and development, one that, ResearchAndMarkets.com has predicted will grow at an astonishing rate of 25.91% CAGR for the years 2018-2022. At the moment almost every major Canadian marijuana company has either a beverage in development or edibles underway in a test kitchen. Edibles and beverages are made from oils and compounds removed from the plants by volatile or non-volatile extraction methods. One way of investing in this developing market lies in investing in those companies that are extracting THC and CBDs from marijuana and then selling it business to business for use in either medical marijuana or as food grade marijuana.
North Bud Farms (CSE: NBUD) is building out its 95 acre site in Low Quebec where it is in within 10 km of a major hydro power plant. Construction is scheduled to be finished Q1 2019 and at the moment is on time and within budget.
The company is also in the process of applying of for a production license under the Access to Cannabis for Medical Purposes Regulation (ACMPR). North Bud has cleverly tagged itself as Marijuana 2.0, in reference to the second wave of legal marijuana slated for October 2019, when the edibles and infused beverage market will be open for business. The company’s strategy is to supply two underserved markets by producing and selling certified pharmaceutical grade cannabis and GMP standard raw cannabis for the food and beverage industry. The company also intends to develop and market new products.
To that end it has recently signed a number of agreements that will help turn its words into action. On September 27, 2018 the company announced that it had signed an agreement with American firm Made By Science to license its cannabinoid infusion technology for food and beverage platform.
On October 17, 2018 North Bud announced that it had created a distribution company, “1017,” so named to commemorate the date of marijuana legalization Canada, and signed a letter of intent to acquire Janey’s, one of the six licensed marijuana accessory distributers in Ontario. Janey’s is also engaged in marijuana product development. North Bud intends to develop multiple products over a variety of product segments under the 1017 brand.
As of November 15, 2018 North Bud Farms, (CSE: NBUD) was trading at $0.25.
Given the predicted explosion in the marijuana consumables and edibles market laying a bet or two on companies in that field makes sense and one such company that bears keeping an eye on is Arev Brands International (CSE: AREV), formally Arev Nutrition Sciences. Arev originally saw life as a developer and marketer of coconut oil based health products. It is focussed on two distinct market sectors, consumer products and manufacturing as an ingredients supplier. Along the way the company also developed a unique extraction technology and this is where they fit into the consumables market segment.
In a press release on Bloomberg the company announced that it had reached a major milestone in extraction development with its partner Alternative Extracts Inc. Using its proprietary extraction system Arev has developed a
system that preserves flavour and aroma and which in the case of beverages may lengthen shelf life. It intends to manufacture finished oil products with proprietary strains bred to specifically address key health issues: anxiety, pain management, central nervous system disorders, insomnia and libido.
Arev also has an exclusive distribution agreement with the award winning full line of BARE Topical products.
In September 2018 the company completed its acquisition of BC Bud Depot. BCBD has one of the world’s largest cannabis seed banks. Over the last 14 years BCBD has won over 40 awards and was the first Canadian company to win an international award with “BC God Bud,” now Canada’s most award winning strain of all time.
On November 15, 2018 AREV was trading at $0.365.
This blog should not be construed as investment advice. Every investor is obligated to perform his or her own due diligence. In the interests of transparency Arev and North Bud Farms are both Momentum Public Relations clients.
- Published in AREV Nutrition Sciences, Blog, Marijuana, Medical Marijuana, NorthBud
AREV Brands International Ltd. announces Success in Terpene Blends on 1st Degree Burns and Insect Bites
Momentum Public Relations
Press Release: November 14, 2018
AREV Brands International Ltd. (” AREV ” or the “Company”) ( CSE – AREV ), is pleased to announce AREV Brands International Ltd. has has reached another major milestone in one of its several joint development projects with Alternative Extracts Inc. Further to the research work reported on September 20, 2018, terpenes from non-regulated sources were used to formulate a proprietary composition for burns and insect bites. As noted in peer-reviewed literature, terpene synthesis is vital for cannabinoid synthesis as it provides the GPP molecule for CBGA synthesis.
As evidenced in these images (which was first taken within 18 hours of the burn accident, and in 24-hour succession thereafter), the blisters from the burn were completely eliminated within 4 days from the first application. The patient in this case is a 50-year old woman who has a known history of keloid formation. It is noted that the patient did not develop any infection.
AREV extracted the valuable terpenes from selected non-regulated plant materials and exudates from trees using its extraction systems that it acquired from Alternative Extracts Inc. The composition was formulated in collaboration between AREV and AEI. The mechanism of the composition is believed to be the result of the poly-molecular function of the terpenes.
The company cautions, that although these results are encouraging, a wider sample population is required. A formal study will be conducted in the coming months.
Burn data from World Health Organization shows that:
- – In India, over 1,000,000 people are moderately or severely burnt every year.
– Nearly 173,000 Bangladeshi children are moderately or severely burnt every year.
– In Bangladesh, Colombia, Egypt and Pakistan, 17% of children with burns have a temporary disability and 18% have a permanent disability.
– Burns are the second most common injury in rural Nepal, accounting for 5% of disabilities.
– In 2008, over 410,000 burn injuries occurred in the United States of America, with approximately 40,000 requiring hospitalization.
Mike Withrow commented “Although we are pleased to have been able to minimize the pain and scarring in this burn patient, the results from the use of our proprietary blend of natural compounds warrants further testing and trials.”
Dr. Adrian Wade, Chief Science Officer, of Alternative Extracts Inc. commented, “This collaboration continues to produce highly effective compounds and formulations. Terpenes have demonstrated to play an important role in an increasing number of natural health and medical products.”
Seek safe harbor and forward looking statements.
For further information, contact Mike Withrow, mike.withrow.vn@gmail.com, (778) 896-6536?.
On behalf of the Board,
Mike Withrow
CEO & Director
About AREV Brands International Ltd.
AREV Brands International Ltd. (“AREV”) produces and delivers functional compounds and ingredients from its world-class extraction systems. AREV is revolutionizing the current delivery method of terpenes, cannabinoids and flavonoids. These premium ingredients and formulations are used in products targeted for sale in the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV innovates through extraction to produce extracts from specific selected plant and exude from trees that address 5 areas of health including Anxiety, Pain Management, Insomnia, Central Nervous System Disorders & Libido.
- Published in AREV Nutrition Sciences, Business, Life Sciences, Medical Marijuana, News Home, Technology
DIAGNOS Announces Today the Addition of a Strategic Partner in the Country of Mexico
Momentum Public Relations
Press Release: November 13, 2018
DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today the addition of a strategic partner in the country of Mexico. This agreement will enlarge the footprint coverage of DIAGNOS’ offering for monitoring diabetic patients through our first partner in that country.
“Today we all (my family and I), accepted unanimously to go with DIAGNOS in this adventure, we truly believe both of us will do great and together will achieve important objectives”, declares Quim. Sergio Galindo, founder and owner of Axmilab. “Mr. Andre Larente visited me in Monterrey city, my hometown at my brand new office, we clicked right away because we both are men of one vision: to provide the best diagnostic technology to prevent and leverage the health quality of people.” “I also met Mr. Georges Herbert Chairman of DIAGNOS Inc, during his visit to Mexico City. Very important reasons for me to partner with DIAGNOS, because I partner with true people”, finished Quim. Sergio Galindo.
“We express our gratitude and celebrate along with Axmilab family their decision to collaborate with us, the first step is to prepare ourselves for key projects in different states of Mexico”, mentions Mr. Guillermo Moreno, Vice President of DIAGNOS, Latin America.
About AXIMILAB
Axmilab is a Mexican company with more than 24 years of experience by manufacturing and distributing products in the health sector. His founder, Quim. Sergio Galindo, has successfully driven the business since its conception in 1994, now with the support of his family, is growing exponentially as an example, they’ve been a supplier for IMSS (by winning contracts in the last 13 consecutive years in the diabetes area). Its dominant territory is Northern Mexico, headquarters is in Monterrey, N.L., also covering Mexico City, Sonora, Queretaro, Chiapas, Chihuahua, Durango, Jalisco, Yucatan, San Luis Potosi States among others. Since 1998, Axmilab has been working at all levels of Government, also represents major brands such as Roche, J&J, Licon, PKL, Alifax.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information is available at www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, President | Josh Falle |
DIAGNOS Inc. | Momentum PR |
Tel: 450-678-8882 ext. 224 | Tel: 514-416-4656 |
alarente@diagnos.ca | josh@momentumpr.com |
- Published in Diagnos, Life Sciences, News Home, Technology
AREV Brands International Ltd. Announces Asset Purchase Agreement Completed to Bare Topicals from Alternative Extracts Inc.
Momentum Public Relations
Press Release: November 9, 2018
AREV Brands International Ltd. (” AREV ” or the “Company”) ( CSE – AREV ), is pleased to announce it has completed the asset purchase (the “Acquisition Agreement”) dated November 9, 2018 with Alternative Extracts Inc. (“AEI”). To acquire 100% of the Bare Topicals assets in consideration for issuance of 500,000 common shares of the Company at a deemed price of $0.32 per share issued by the Company, for an aggregate value of $160,000.
Bare Brands is a Line of Award Winning Cannabis Infused Topical Products aim to provides safe alternatives to achieving significant pain relief and treatment of skin conditions.
2016
Bio Cup – 1st place topical (Magik)
Bio Cup – 2nd Place topical (SPF 420)
Bio Cup – 1st place topical people’s choice (Magik)
Bio Cup – 2nd Place topical people’s choice (SPF 420)
Bio Cup – 2nd Place best product (overall for the event) (SPF 420)
Karma Cup – 3rd place topical (Magik)
2017
Okanagan Cannabis Cup – 2nd place topical (Magik)
High Times Cannabis Cup – 2nd Place topical (Magik)
Karma Cup – 1st place topical (Recover)
Karma Cup – 3rd place topical (Magik)
2018
The Canna Cup – 1st place topical
The Grey Area Festival – 2nd Place topical (Releaf)
Okanagan Cannabis Cup – 2nd Place topical (Recover)
Karma Cup – 2nd Place topical (Recover)
The most awarded topical company in Canada.
Mike Withrow, CEO for AREV Brands International states “This acquisition is another that adds to the portfolio of products AREV continues to assemble while working on obtaining ACMPR Licencing to sell any of our cannabis based products. In the meantime we are preparing the Bare Topicals herbal line for production.”
The Company, effective immediately, has issued 500,000 stock options to Directors, Officers and Consultants of the Company at a price of $0.41 for a period of 5 years from the issuance date. These options will vest immediately.
Seek safe harbor and forward-looking statements.
For further information, contact Mike Withrow, mike.withrow.vn@gmail.com.
On behalf of the Board,
Mike Withrow
CEO & Director
About AREV Brands International Ltd.
AREV Brands International Ltd. (“AREV”) produces and delivers functional compounds and ingredients from its world-class extraction systems. AREV is revolutionizing the current delivery method of terpenes, cannabinoids and flavonoids. These premium ingredients and formulations are used in products targeted for sale in the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV innovates through extraction to produce extracts from specific selected plant and exude from trees that address 5 areas of health including Anxiety, Pain Management, Insomnia, Central Nervous System Disorders & Libido.
- Published in AREV Nutrition Sciences, Business, Life Sciences, Medical Marijuana, News Home, Technology
CROP Working ‘Rapidly’ To Vertically Integrate California Production, Extraction, Distribution And Retail
Momentum Public Relations
Press Release: November 7, 2018
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today that it is working towards complete vertical integration in California. Processing continues at Humboldt Farm and new automation equipment has arrived to increase efficiencies and continually increase return on investment (ROI) of finished inventory.
Additionally, CROP’s Emerald Heights retail brand has just completed the stage three interview process with the City of San Bernardino which is a major hurdle before the final licensing review to open its first California retail location. CROP is currently going through the process of opening two Emerald Heights locations in Italy, one in Nevada and one at the aforementioned location in California.
The company’s tenant is currently accepting and reviewing bids from distributors to represent the company’s production under its Hempire, Evolution and White Rhino brands. The tenant has also applied for its own distribution license to represent its own production and the production of other complimentary producers in the region which will result in another license in the growing portfolio of tenant licensees.
CROP has also been notified that the tenants are preparing an extraction license application for Humboldt Farm which will maximize the ROI and broaden the range of Stock Keeping Units (‘SKUs’) available to retail locations.
CROP has submitted its building plans to the Humboldt County Building and Planning Department to increase the production of the California facility at a cost of $1,000,000 of which $250,000 has already been spent. The increased production will result in an additional ~12,000 pounds of high-quality cannabis and 3,000 pounds of secondary material per year.
CROP Infrastructure CEO, Michael Yorke, stated: “The significance of fully vertically integrating cannot be understated and we are working towards that end as rapidly as is practicable. As with CROP’s worldwide tenant strategy, production is always focused on high quality at low cost. With extraction and retail verticals now in process, the opportunity to maximize ROI on a significant scale presents the opportunity to control CROP’s tenant destiny and maximize future profits.”
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, an 1,865 acre CBD farm, extraction in Nevada with international focuses in Jamaica and Italy and a joint venture on West Hollywood and San Bernardino dispensary applications.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
- Published in Business, CROP Infrastructure, Marijuana, Medical Marijuana, News Home
DIAGNOS Announces Private Placement of Common Stocks and Stock Warrants
Momentum Public Relations
Press Release: November 6, 2018
DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces a private placement (“Private Placement”) of up to 16,160,000 units (each a “Unit”) issued at $0.05 per Unit for gross proceeds of up to $808,000. Each Unit consists of;
- one common share (“Share”), and
- one stock warrant (“Warrant”) entitling the holder to purchase one Share per Warrant at a price of $0.05 per Share, for a period of 24 months from the date of issuance of the Warrant.
The proceeds will be used mainly to fund sales and marketing as well as administrative expenses.
It is expected that one participant in the Private Placement will become a “related party” of DIAGNOS within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). It is expected that 15,000,000 Units will be subscribed by the participant. The participant will exercise, as a result of the Private Placement, control up to 19.10% of the common shares of DIAGNOS. The transaction is exempt from the valuation requirement and the minority approval requirement prescribed in MI 61-101 based on the fact that the fair market value of the related party’s participation in the Private Placement does not exceed 25% of DIAGNOS’ market capitalization prior to the closing of the Private Placement.
Shares issued as part of the Private Placement as well as the underlying Shares to be issued upon exercise of the Warrants are subject to a statutory four-month hold period from the date of issuance.
Closing of the Private Placement is scheduled for November 9, 2018. The Private Placement is subject to receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange, as well as the execution of formal documentation.
All monies quoted in this press release shall be stated and paid in lawful money of Canada.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
Mr. André Larente, President | Josh Falle | ||
DIAGNOS Inc. | Momentum PR | ||
Tel: 450-678-8882 ext. 224 | Tel: 514-416-4656 | ||
alarente@diagnos.ca | josh@momentumpr.com |
- Published in Business, Diagnos, Life Sciences, News Home, Technology
Sirona Biochem Begins Proof of Efficacy Clinical Trial for TFC-1067
Momentum Public Relations
Press Release: November 6, 2018
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company“) reported today the successful launch of the clinical trial for skin-lightener TFC-1067 with leading dermatologist Dr. Zoe Draelos.
In September, Sirona reported that the Company was awaiting final results from the second clinical trial for the Human Repeat Insult Patch Test (HRIPT). This test was performed on 110 people to assess safety of TFC-1067. The data confirmed TFC-1067 as a non-sensitizer, providing the final support needed for toxicologist approval.
Following completion of the preliminary studies and toxicologist approval, the Company has begun the enrollment process for the clinical trial. All material, including the formulated TFC-1067 cream, has been delivered to the clinical-trial center in North Carolina and final International Review Board approval is pending.
Once patients have been enrolled, the twelve-week assessment of TFC-1067 will begin under the supervision of Dr. Draelos, who has conducted clinical trials for many top pharmaceutical companies worldwide. The Company looks forward to using the results to further and solidify discussions with partners in North America and Asia, as final confirmation of TFC-1067’s safety and efficacy as a skin-lightening agent.
“This clinical trial marks a major milestone for Sirona Biochem and its scientific team,” said Dr. Howard Verrico. “With the anticipated start of the clinical trial for Sirona’s SGLT-2 inhibitor, TFC-039, by partner Wanbang Biopharmaceuticals Co. Ltd. this year, we will have two compounds simultaneously in clinical trials. This highlights the strength of Sirona’s platform technology in creating novel compounds for both therapeutic and cosmetic indications with excellent potential for full commercialization.”
About Dr. Zoe Draelos
Dr. Zoe Draelos is a clinical and research dermatologist based in High Point, North Carolina. Dr. Draelos, supported by a team of highly skilled scientists, is the head of the Dermatology Consulting Services (DCS) research organization, aimed at facilitating research, consulting and communication services to the pharmaceutical and cosmetic industries. The clinical trial center runs assessments on different skin, hair and nail conditions, such as acne, psoriasis, hair loss and aging.
With over thirty years of experience, Dr. Draelos has been recognized many times over the years for her cutting-edge research, including the lifetime achievement award from Health Beauty America and the Society of Cosmetic Chemists. A pioneer in the field of cosmetic dermatology, Dr. Draelos continues to work with lead cosmetic and pharmaceutical companies as well as furthering her own research in the dermatology space.
Dr. Draelos was a past vice-president of the American Academy of Dermatology and is a Consulting Professor of Dermatology at Duke University. She has authored over 300 articles, 8 books and has shared her expertise across different media.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
- Published in Life Sciences, News Home, Sirona Biochem
CROP Completes 2018 Harvest at Nevada CBD Farm and Prepares First Shipment
Momentum Public Relations
Press Release: November 6, 2018
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announces an update on its 1,865-acre hemp-CBD farm.
CROP’s tenant has now completed the harvest of 240 acres of CBD hemp. Samples have been sent out for independent testing to determine CBD concentrations and for a Certificate of Analysis (‘COA’). Once the COA has been received, the CBD will be shipped to the company’s partnertoll processor to produce CBD isolate, as announced October 10, 2018. The company has also completed site testing at the entire Hemp-CBD project and soil is ready for 2019 planting. The company is developing lines of CBD capsule and tinctures to maximize its returns from its CBD production. The hemp & CBD isolate, and related products will be sold under the company’s Hempire and Tiff CBD brands and utilized for the Canna Drink beverage line.
Furthermore, the company’s tenant is now accepting inquiries for bulk orders of CBD isolate from the 2018 production.
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, an 1,865 acre CBD farm, extraction in Nevada with international focuses in Jamaica and Italy and a joint venture on West Hollywood and San Bernardino dispensary applications.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Company Contact
Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in CROP Infrastructure, Marijuana, Medical Marijuana, News Home
ATW Tech Announces Signature of a Letter of Intent for Major Acquisition of Greywolf Entertainment Group
Momentum Public Relations
Press Release: November 6, 2018
ATW Tech Inc. (“ATW Tech”) (TSX-V: ATW) announces today the signature of a letter of intent for the acquisition from Fastrack Trust (the “Trust”) of all of the outstanding shares of 6855318 Canada Ltd. and 6890202 Canada Ltd. (“Greywolf Entertainment Group” or “Greywolf”).
Greywolf Entertainment Group, based in Calgary, provides turnkey full commercial production for interactive TV and/or voting networks required for such shows for landline and mobile consumers. Greywolf’s subsidiaries include Triton Global Business Services Inc. (“Triton”) and Fastrack Global Billing Networks Inc. (“Fastrack”). Triton is a North American clearinghouse that provide billing and networks for phone bills in North America and over 40 other countries. Triton has been listed in the top 300 technology companies from Canada several times. Fastrack is a North American inter-exchange carrier providing networks to its switch centers that intelligently routes consumer traffic to optimized billing or response solutions. Its network is designed to handle mass calling for both short and long periods of time, using its own robust backbone Standard Internet Protocol (SIP) networks to transport traffic anywhere in the world. For the unaudited financial year ended December 31, 2017, Greywolf’s revenues were $10.0 million.
The letter of intent contemplates a purchase price of $2.95 million, which is subject to certain adjustments and payable through a cash payment of $2.0 million at closing, a vendor take-back note of $0.3 million payable in 30 equal monthly installments and $0.65 million worth of common shares of ATW Tech. No commission is payable and no change of control will result.
“We are proud to come to an agreement on this strategic acquisition of Greywolf that will help us consolidate our position in the Canadian carrier billing market, accelerate our growth, while almost doubling our revenues, and benefiting from significant cost synergies. Along with the contemplated divestiture of the Atman division announced on September 17, 2018, which represented 9.5% of ATW Tech’s revenues in 2017, this contemplated acquisition reflects our will and strategy to concentrate our activities on our core integrated payment, interactive communication and voting platforms. This acquisition shall be the first step of our acquisition growth plan with an international reach expected for 2019” said Michel Guay, President and CEO of ATW Tech.
The closing of this transaction between ATW Tech and Greywolf, which are dealing at arm’s length, is conditional among other things on ATW Tech carrying out a satisfactory due diligence on Greywolf, obtaining satisfactory financing and all necessary regulatory approvals. Closing of this transaction is expected before the end of 2018.
Update on PlusMobile Acquisition
In August 2017, ATW Tech announced the signature of a letter of intent for the contemplated acquisition of PlusMobile LLC (“PlusMobile”) and all of its subsidiaries. PlusMobile is based in Argentina and offers premium products on mobile phones with carrier billing agreements in 6 countries of Latin America and offers quality contents such as mobile apps in the business segments of education, kids, entertainment as well as mobile marketing via SMS. Although ATW Tech’s goal is still to expand its distribution network and diversify its operations internationally, especially in the Latin America fast growing carrier billing market, ATW Tech has decided to put that contemplated acquisition on hold temporarily due to the recent volatility in the Argentina economy and in particular in the local currency. ATW Tech will revisit in due course if and when market conditions warrant.
Forward-Looking Statements Disclaimer
Certain statements in this press release may be forward-looking. Such statements include those with respect to the closing of the acquisition of Greywolf and ATW Tech’s growth and acquisition strategy. Although ATW Tech believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurances that its expectations will be achieved. Such assumptions, which may prove incorrect, include the following: (i) the conditions for the transaction will be met, including a satisfactory due diligence by ATW Tech on Greywolf and ATW Tech securing financing on satisfactory terms, (ii) ATW Tech and the Trust will successfully negotiate and enter into a purchase agreement and other documents relating to the transaction, (iii) ATW Tech will successfully obtain the necessary regulatory approvals for the acquisition of Greywolf on commercially-acceptable terms, (iv) the acquisition of Greywolf will allow ATW Tech to achieve the anticipated cost synergies and (v) ATW Tech will successfully identify and conclude additional acquisitions outside of Canada in 2019. A description of other risks affecting ATW Tech’s business and activities appears under the heading “Risks Factors and Uncertainty” on pages 9 and 10 of ATW Tech’s 2017 annual management’s discussion and analysis, which is available on SEDAR at www.sedar.com. No assurance can be given that any events anticipated by the forward-looking information in this press release will transpire or occur, or if any of them do so, what benefits that ATW Tech will derive therefrom. ATW Tech disclaims any intention or obligation to update or revise any forward-looking statements in order to account for any new information or any other event, except as required under applicable law. The reader is warned against undue reliance on these forward-looking statements.
Additional information regarding ATW Tech is available on SEDAR www.sedar.com
- Published in Atmanco, Financial Technology, News Home, Technology